BMRA vs ICCC: stock comparison and AI forecast
Biomerica Inc (BMRA) and Immucell Corp /De/ (ICCC) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BMRA Biomerica Inc
- Price
- $1.61 -26.8% · 6M
- Market Cap
- $7M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
ICCC Immucell Corp /De/
- Market Cap
- $90M
- P/E Ratio
- 497.6x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ICCC is 12.2 times larger than BMRA by market capitalization ($90M against $7M).
- ICCC turns 2.6% of its revenue into net income, against -116.4% for BMRA.
- BMRA carries 1.21 times debt per unit of equity, against 0.49 times for ICCC.
- Both companies share the SEC industry classification In Vitro & In Vivo Diagnostic Substances.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BMRA | ICCC |
|---|---|---|
| Market Cap | $7M | $90M |
| P/E Ratio | – | 497.63x |
| P/B Ratio | 2.03x | 2.88x |
| EPS | $-0.81 | $0.02 |
| Book Value/Share | $0.79 | $3.45 |
| Revenue/Share | – | $3.38 |
| FCF/Share | – | $0.46 |
Profitability & Margins
| Metric | BMRA | ICCC |
|---|---|---|
| ROE | -141.9% | 2.5% |
| ROA | -64.2% | 1.7% |
| ROIC | -95.8% | 9.2% |
| Gross Margin | 12.1% | 40.3% |
| Operating Margin | -112.7% | 12.6% |
| Net Margin | -116.4% | 2.6% |
| EBT Margin | -86.3% | 2.8% |
| Tax Rate | -0.6% | 7.8% |
Financial Health
| Metric | BMRA | ICCC |
|---|---|---|
| Current Ratio | 1.91x | 4.75x |
| Quick Ratio | 1.33x | 2.71x |
| D/E Ratio | 1.21x | 0.49x |
| Financial Leverage | 2.21x | 1.49x |
| Interest Coverage | -7344.2x | 20.4x |
| Working Capital | $3M | $17M |
Cash Flow
| Metric | BMRA | ICCC |
|---|---|---|
| Operating Cash Flow | -$3M | $6M |
| Free Cash Flow | – | $4M |
| Capital Spending | – | -$2M |
| OCF Growth YoY | – | 132.6% |
| FCF Growth YoY | – | 138.9% |
| FCF/Sales | – | 13.7% |
| CapEx/Sales | – | 5.5% |
Operational Efficiency
| Metric | BMRA | ICCC |
|---|---|---|
| Asset Turnover | – | 0.66x |
| Receivables Turnover | – | 10.6x |
| Inventory Turnover | 2.6x | 2.0x |
| Fixed Assets Turnover | – | 1.5x |
| Days Sales Outstanding | – | 34 days |
| Days Inventory | 139 days | 181 days |
| Payables Period | 127 days | 56 days |
| Cash Conversion Cycle | – | 159 days |
Income Statement
| Metric | BMRA | ICCC |
|---|---|---|
| Total Revenue | – | $31M |
| Operating Income | -$5M | $4M |
| Net Income | -$5M | $790K |
| R&D Expense | $790K | $2M |
| SG&A Expense | $5M | $10M |
| Cost of Goods Sold | $4M | $18M |
Dividend & Shareholder Information
| Metric | BMRA | ICCC |
|---|---|---|
| Shares Outstanding | 5M | 9M |
| Net Income Growth | – | -40.5% |
BMRA vs ICCC: stock comparison and AI forecast
Which is bigger, BMRA or ICCC?
ICCC is 12.2 times larger than BMRA by market capitalization ($90M against $7M).
Which one does Intratio's AI model rank higher, BMRA or ICCC?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.